Placebo-Controlled, Randomized Clinical Trial of Azimilide for Prevention of Ventricular Tachyarrhythmias in Patients With an Implantable Cardioverter Defibrillator
Authors:
- Paul DorianPDPaul Dorian
- Martin BorggrefeMBMartin Borggrefe
- Hussein R. Al-KhalidiHAHussein R. Al-Khalidi
- Stefan H. HohnloserSHStefan H. Hohnloser
- Jose M. BrumJBJose M. Brum
- Daljit S. TatlaDTDaljit S. Tatla
- Johannes BrachmannJBJohannes Brachmann
- Robert J. MyerburgRMRobert J. Myerburg
- David S. CannomDCDavid S. Cannom
- Michael van der LaanMLMichael van der Laan
- Michael J. HolroydeMHMichael J. Holroyde
- Igor SingerISIgor Singer
Open Access
- 14 December 2004
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Circulation
- Vol. 110 (24) , 3646-3654
Abstract
Background— Although implanted cardioverter defibrillators (ICDs) effectively treat sustained ventricular tachyarrhythmias, up to 50% of ICD recipients eventually require concomitant antiarrhythmic drug therapy to prevent symptomatic arrhythmia recurrences and hence reduce the number of device therapies. Methods and Results— A total of 633 ICD recipients were enrolled in a randomized, double-blind, placebo-controlled study to evaluate the effect of daily doses of 75 or 125 mg of azimilide on recurrent symptomatic ventricular tachyarrhythmias and ICD therapies. Total all-cause shocks plus symptomatic ventricular tachycardia (VT) terminated by antitachycardia pacing (ATP) were significantly reduced by azimilide, with relative risk reductions of 57% (hazard ratio [HR]=0.43, 95% CI 0.26 to 0.69, P =0.0006) and 47% (HR=0.53, 95% CI 0.34 to 0.83, P =0.0053) at 75- and 125-mg doses, respectively. The reductions in all-cause shocks with both doses of azimilide did not achieve statistical significance. The incidence of all appropriate ICD therapies (shocks or ATP-terminated VT) was reduced significantly among patients taking 75 mg of azimilide (HR=0.52, 95% CI 0.30 to 0.89, P =0.017) and those taking 125 mg of azimilide (HR=0.38, 95% CI 0.22 to 0.65, P =0.0004). Five patients in the azimilide groups and 1 patient in the placebo group had torsade de pointes; all were successfully treated by the device. One patient taking 75 mg of azimilide had severe but reversible neutropenia. Conclusions— Azimilide significantly reduced the recurrence of VT or ventricular fibrillation terminated by shocks or ATP in ICD patients, thereby reducing the burden of symptomatic ventricular tachyarrhythmia.Keywords
This publication has 25 references indexed in Scilit:
- Long-Term Comparison of the Implantable Cardioverter Defibrillator Versus AmiodaroneCirculation, 2004
- Mortality in Patients After a Recent Myocardial InfarctionCirculation, 2004
- Effectiveness of implantable defibrillators for preventing arrhythmic events and deathJACC, 2003
- Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection FractionNew England Journal of Medicine, 2002
- Is electrical storm in ICD patients the sign of a dying heart? Outcome of patients with clusters of ventricular tachyarrhythmiasEP Europace, 2000
- Evaluation of the bias in using the time to the first event when the inter-event intervals have a Weibull distributionStatistics in Medicine, 1999
- The CASCADE study: Randomized antiarrhythmic drug therapy in survivors of Cardiac Arrest in SeattleThe American Journal of Cardiology, 1993
- Effect of sotalol on ventricular fibrillation and defibrillation in humansThe American Journal of Cardiology, 1993
- Sample size for Poisson regressionBiometrika, 1991
- Cox's Regression Model for Counting Processes: A Large Sample StudyThe Annals of Statistics, 1982